MedscapeIdelalisib and rituximab extends survival in CLL patientsThe Oncology Report… rituximab extends survival in CLL patients. Adding idelalisib to rituximab significantly extends survival in patients with heavily pretreated relapsed chronic lymph…
Idelalisib Shows Efficacy in Relapsed CLL and Lymphoma – Medscape
Idelalisib Shows Efficacy in Relapsed CLL and LymphomaMedscapeThis trial showed that idelalisib used in combination with rituximab (Rituxan, Genentech/Roche) offered an option for patients with relapsed CLL who were unable to tolerate chemotherapy. The…
Luis Collazo dedicates fight to LI girl – Newsday
|
Luis Collazo dedicates fight to LI girl
Newsday Genatt met Collazo through her trainers Scooter Honig and Eddie O’Boyle at Competitive Edge Athletics in Port Washington when she was preparing for kidney transplant surgery in 2010. Genatt speaks at meetings of Nephrologists and organizes fundraising … |
Illumina, LabCorp Ink Multi-Year Deal – Analyst Blog – NASDAQ
Illumina, LabCorp Ink Multi-Year Deal – Analyst BlogNASDAQLast week, ILMN announced plans to enter emerging markets in mid-2014 by launching a human leukocyte antigen (HLA) typing product, developed using its NGS platform. The HLA typing assays that LH…
Rheuminations: 2013 Year in Review – MedPage Today
MedPage TodayRheuminations: 2013 Year in ReviewMedPage TodayHowever, by the end of 2013 we now have many comparator trials that show after failing an initial TNF inhibitor, there is equivalent or better efficacy when targeting different mechanisms with…
Illumina Sketches Strategy to Push NGS into Reproductive Health, Disease … – GenomeWeb
|
Illumina Sketches Strategy to Push NGS into Reproductive Health, Disease …
GenomeWeb HLA typing represents another $300 million market opportunity, according to the company. Illumina has already started to penetrate some of these new markets, as evidenced by a shift in its customer base. Over the last five years, Illumina’s revenue … |
Health Care Industry Professional with Personal Connection to Organ Donation … – TheAlternativePress.com
TheAlternativePress.com |
Health Care Industry Professional with Personal Connection to Organ Donation …
TheAlternativePress.com Cheryl Cohen, a Chesterfield, NJ resident and healthcare industry professional with more than 25 years of experience, has a personal and long-standing connection to organ and tissue donation. “Eight years ago, my brother had a heart transplant,” said … |
Bioresorbable Scaffold Designed for PAD Yields Good Early Results – TCTMD
Bioresorbable Scaffold Designed for PAD Yields Good Early ResultsTCTMDAll patients were treated with the Esprit everolimus-eluting BVS (Abbott Vascular, Santa Clara, CA), which is designed to fully metabolize within 18 months of implantation. Acute pro…
Save a Baby's Life and Save a Second Life with Baby's Umbilical Cord Blood … – Family Research Council (blog)
|
Save a Baby’s Life and Save a Second Life with Baby’s Umbilical Cord Blood …
Family Research Council (blog) The first umbilical cord blood stem cell transplant was performed in October 1988, for a 5-year-old child with Fanconi anemia, a serious condition where the bone marrow fails to make blood cells. That patient is currently alive and healthy, 25 years … |
UCLA researchers develop risk calculator to predict survival in heart failure … – UC Los Angeles
|
UCLA researchers develop risk calculator to predict survival in heart failure …
UC Los Angeles A UCLA team has developed an easy-to-use “risk calculator” that helps predict heart failure patients’ chances of survival for up to five years and assists doctors in determining whether more or less aggressive treatment is appropriate. Given that heart … |